about us | leadership | team | board of directors | scientific advisors
Our lead program, ALPN-101, demonstrated preclinical activity in inflammatory arthritis and multiple sclerosis mode… twitter.com/i/web/status/10543…
Yesterday at 2:00 pm
We’re planning to bring ALPN-101, our dual ICOS/CD28 antagonist, to #arthritis patients. We will present preclinica… twitter.com/i/web/status/10507…
October 12, 2018 4:02 pm
© 2018 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.